Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease.

Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, Schindler S, Carrillo MC, Hendrix JA, Ross A, Illes J, Ramus C, Fifer S.

Alzheimers Dement. 2018 Oct 3. pii: S1552-5260(18)33492-7. doi: 10.1016/j.jalz.2018.07.220. [Epub ahead of print] Review.

PMID:
30316776
2.

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease.

Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2018 Sep 21. pii: S1552-5260(18)33248-5. doi: 10.1016/j.jalz.2018.06.3059. [Epub ahead of print]

PMID:
30266303
3.

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M.

Brain. 2018 Oct 1;141(10):3065-3080. doi: 10.1093/brain/awy229.

4.

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R.

Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5.

5.

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

PMID:
30217935
6.

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-To-Moderate Alzheimer's Disease: A Phase 2, Open Label Extension Study.

Salloway S, Marshall GA, Lu M, Brashear HR.

Curr Alzheimer Res. 2018 Aug 20. doi: 10.2174/1567205015666180821114813. [Epub ahead of print]

PMID:
30129411
7.

Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.

Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, Morris JC, Maruff P, Bateman RJ; Dominantly Inherited Alzheimer Network.

Ann Neurol. 2018 Sep;84(3):424-435. doi: 10.1002/ana.25299. Epub 2018 Aug 25.

PMID:
30014553
8.

What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.

Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2018;5(3):171-174. doi: 10.14283/jpad.2018.23.

PMID:
29972209
9.

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques.

Ikonomovic MD, Fantoni ER, Farrar G, Salloway S.

Alzheimers Res Ther. 2018 Jun 23;10(1):60. doi: 10.1186/s13195-018-0387-6.

10.

Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation.

Leoutsakos JS, Yan H, Anderson WS, Asaad WF, Baltuch G, Burke A, Chakravarty MM, Drake KE, Foote KD, Fosdick L, Giacobbe P, Mari Z, McAndrews MP, Munro CA, Oh ES, Okun MS, Pendergrass JC, Ponce FA, Rosenberg PB, Sabbagh MN, Salloway S, Tang-Wai DF, Targum SD, Wolk D, Lozano AM, Smith GS, Lyketsos CG.

J Alzheimers Dis. 2018;64(2):597-606. doi: 10.3233/JAD-180121.

PMID:
29914028
11.

Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.

Salloway SP, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, Rofael H, Ketter N, Wang D, Liu E, Carr S, Black RS, Brashear HR.

J Alzheimers Dis. 2018;64(3):689-707. doi: 10.3233/JAD-171157.

PMID:
29914022
12.

Improving Evaluation of Patients With Cognitive Impairment With Amyloid Positron Emission Tomography.

Salloway S.

JAMA Neurol. 2018 Sep 1;75(9):1045-1046. doi: 10.1001/jamaneurol.2018.1010. No abstract available.

PMID:
29889928
13.

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

PLoS One. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018.

14.

Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.

Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, Jack C Jr, Ances BM, Ringman JM, Marcus DS, Ghetti B, Farlow MR, Danek A, Levin J, Yakushev I, Laske C, Koeppe RA, Galasko DR, Xiong C, Masters CL, Schofield PR, Kinnunen KM, Salloway S, Martins RN, McDade E, Cairns NJ, Buckles VD, Morris JC, Bateman R, Sperling RA; Dominantly Inherited Alzheimer Network.

Brain. 2018 May 1;141(5):1486-1500. doi: 10.1093/brain/awy053.

PMID:
29522171
15.

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.

Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Perneczky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M.

Brain. 2018 Apr 1;141(4):1186-1200. doi: 10.1093/brain/awy008.

16.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.

Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

PMID:
29429971
17.

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Lancet Neurol. 2018 Mar;17(3):241-250. doi: 10.1016/S1474-4422(18)30028-0. Epub 2018 Feb 1.

PMID:
29397305
18.

Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive Disorder.

Rasmussen SA, Noren G, Greenberg BD, Marsland R, McLaughlin NC, Malloy PJ, Salloway SP, Strong DR, Eisen JL, Jenike MA, Rauch SL, Baer L, Lindquist C.

Biol Psychiatry. 2018 Sep 1;84(5):355-364. doi: 10.1016/j.biopsych.2017.11.034. Epub 2017 Dec 15.

19.

Recruitment of At-Risk Participants for Clinical Trials: A Major Paradigm Shift for Alzheimer's Disease Prevention.

Alber J, Lee AKW, Menard W, Monast D, Salloway SP.

J Prev Alzheimers Dis. 2017;4(4):213-214. doi: 10.14283/jpad.2017.32. No abstract available.

PMID:
29181484
20.

Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease.

Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C.

Alzheimers Dement (Amst). 2017 Jul 1;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017.

21.

Effectiveness of Florbetapir PET Imaging in Changing Patient Management.

Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, Salloway S, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD Sr, Mintun MA.

Dement Geriatr Cogn Disord. 2017;44(3-4):129-143. doi: 10.1159/000478007. Epub 2017 Aug 5.

22.

Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study.

Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, Leung KK, Cardoso MJ, Modat M, Malone IB, Morris JC, Bateman RJ, Marcus DS, Goate A, Salloway SP, Correia S, Sperling RA, Chhatwal JP, Mayeux RP, Brickman AM, Martins RN, Farlow MR, Ghetti B, Saykin AJ, Jack CR Jr, Schofield PR, McDade E, Weiner MW, Ringman JM, Thompson PM, Masters CL, Rowe CC, Rossor MN, Ourselin S, Fox NC; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2018 Jan;14(1):43-53. doi: 10.1016/j.jalz.2017.06.2268. Epub 2017 Jul 22.

PMID:
28738187
23.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A.

Nature. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809.

PMID:
28640269
24.

Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.

Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, Xiong C, Fagan AM, Benzinger T, Buckles V, Erickson KI, Clarnette R, Shah T, Masters CL, Weiner M, Cairns N, Rossor M, Graff-Radford NR, Salloway S, Vöglein J, Laske C, Noble J, Schofield PR, Bateman RJ, Morris JC, Martins RN; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2017 Nov;13(11):1197-1206. doi: 10.1016/j.jalz.2017.03.008. Epub 2017 May 11.

PMID:
28501451
25.

Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, Egan JC, Feldman H, Lappin D, Truyen L, Salloway S, Sperling R, Vradenburg G.

J Prev Alzheimers Dis. 2016 Jun;3(2):114-120. doi: 10.14283/jpad.2016.93. Epub 2016 Mar 4.

26.

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease.

Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Dietzsch J, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Graff-Radford NR, Levin J, Galasko D, Quaid KA, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C.

Sci Rep. 2017 Apr 27;7(1):1225. doi: 10.1038/s41598-017-01327-w.

27.

Alzheimer's Disease in Primary Care: The Significance of Early Detection, Diagnosis, and Intervention.

Herman L, Atri A, Salloway S.

Am J Med. 2017 Jun;130(6):756. doi: 10.1016/j.amjmed.2017.04.001. Epub 2017 Apr 25.

PMID:
28449849
28.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

29.

Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN).

Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0. Epub 2016 Oct 21. Review.

30.

Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669. eCollection 2016.

31.

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.

Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005. Epub 2016 Aug 29.

32.

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A.

Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Update in: Nature. 2017 Jun 21;546(7659):564.

PMID:
27582220
33.

A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease.

Lozano AM, Fosdick L, Chakravarty MM, Leoutsakos JM, Munro C, Oh E, Drake KE, Lyman CH, Rosenberg PB, Anderson WS, Tang-Wai DF, Pendergrass JC, Salloway S, Asaad WF, Ponce FA, Burke A, Sabbagh M, Wolk DA, Baltuch G, Okun MS, Foote KD, McAndrews MP, Giacobbe P, Targum SD, Lyketsos CG, Smith GS.

J Alzheimers Dis. 2016 Sep 6;54(2):777-87. doi: 10.3233/JAD-160017.

34.

BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network.

Brain. 2016 Oct;139(Pt 10):2766-2777. Epub 2016 Aug 12.

35.

White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.

Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Ryan NS, Förster S, Laske C, Schofield PR, Sperling RA, Salloway S, Correia S, Jack C Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

Ann Neurol. 2016 Jun;79(6):929-39. doi: 10.1002/ana.24647. Epub 2016 Apr 27.

36.

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA.

Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002. Review.

PMID:
27012484
37.

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Mar 24;11(3):e0152082. doi: 10.1371/journal.pone.0152082. eCollection 2016. Erratum in: PLoS One. 2016 Sep 20;11(9):e0163669.

38.

Alzheimer's disease.

Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM.

Lancet. 2016 Jul 30;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24. Review.

PMID:
26921134
39.

Two Novel Psychomotor Tasks in Idiopathic Normal Pressure Hydrocephalus.

Rossetti MA, Piryatinsky I, Ahmed FS, Klinge PM, Relkin NR, Salloway S, Ravdin LD, Brenner E, Malloy PF, Levin BE, Broggi M, Gavett R, Maniscalco JS, Katzen H.

J Int Neuropsychol Soc. 2016 Mar;22(3):341-9. doi: 10.1017/S1355617715001125. Epub 2016 Jan 28.

PMID:
26817685
40.

Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.

Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, Langbaum JB, Schneider L, Hendrix S, Wilcock G, Molinuevo JL, Ritchie C, Ousset PJ, Cummings J, Sperling R, DeKosky ST, Lovestone S, Hampel H, Petersen R, Legrand V, Egan M, Randolph C, Salloway S, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2016;3(2):68-74. doi: 10.14283/jpad.2016.97.

PMID:
29210442
41.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM.

JAMA Neurol. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607.

42.

Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia.

Salloway S, Sperling R.

JAMA Neurol. 2015 Oct;72(10):1106-8. doi: 10.1001/jamaneurol.2015.1804. No abstract available.

PMID:
26302229
43.

Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.

Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, Salloway S, Doody R, Aisen P; Task Force Members.

J Prev Alzheimers Dis. 2015 Jun;2(2):128-135.

44.

Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease.

Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Förster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2015 Sep 1;85(9):790-8. doi: 10.1212/WNL.0000000000001903. Epub 2015 Aug 5.

45.

Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease.

Lim YY, Maruff P, Schindler R, Ott BR, Salloway S, Yoo DC, Noto RB, Santos CY, Snyder PJ.

Neurobiol Aging. 2015 Oct;36(10):2709-15. doi: 10.1016/j.neurobiolaging.2015.07.009. Epub 2015 Jul 10.

PMID:
26233262
46.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

47.

Lowering the Floor on Trail Making Test Part B: Psychometric Evidence for a New Scoring Metric.

Correia S, Ahern DC, Rabinowitz AR, Farrer TJ, Smith Watts AK, Salloway S, Malloy PF, Deoni SC.

Arch Clin Neuropsychol. 2015 Nov;30(7):643-56. doi: 10.1093/arclin/acv040. Epub 2015 Jul 11.

PMID:
26164816
48.

Biomarkers, assays, and therapies for Alzheimer disease.

Beriault DR, Diamandis EP, Portelius E, Perret-Liaudet A, Salloway S.

Clin Chem. 2015 Jul;61(7):903-8. doi: 10.1373/clinchem.2015.241901. Epub 2015 May 26. No abstract available.

49.

Building a roadmap for developing combination therapies for Alzheimer's disease.

Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, Salloway S, Trojanowski JQ, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, Carrillo MC, Stephenson D, Snyder H, Liu E, Ware T, McKew J, Fields FO, Bain LJ, Bens C.

Expert Rev Neurother. 2015 Mar;15(3):327-33. doi: 10.1586/14737175.2015.996551. Review.

50.

Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, Salloway S, Schofield PR, Cummings JL, Buckles V, Bateman R, Morris JC; Dominantly Inherited Alzheimer Network.

Brain. 2015 Apr;138(Pt 4):1036-45. doi: 10.1093/brain/awv004. Epub 2015 Feb 15. Erratum in: Brain. 2015 Dec;138(Pt 12):e401.

Supplemental Content

Loading ...
Support Center